Impact of segmentectomy and lobectomy on non-lung cancer death in early-stage lung cancer patients

Eur J Cardiothorac Surg. 2022 Dec 2;63(1):ezac458. doi: 10.1093/ejcts/ezac458.

Abstract

Objectives: This study aimed to analyse the risk of death from non-lung cancer after segmentectomy or lobectomy for early-stage lung cancer.

Methods: A total of 1385 patients underwent lobectomy or segmentectomy for clinical stage 0-I primary lung cancer, with no evidence of recurrence after surgery, between January 2008 and December 2018. Risk factors for non-lung cancer deaths (NLCD) were analysed using multivariable logistic regression analysis. The overall survival (OS) of patients with low and high comorbidities who underwent lobectomy and segmentectomy was compared using a log-rank test.

Results: Patients with NLCD (n = 126) were more likely to have undergone lobectomy than patients with non-recurrence survival (n = 1259). Multivariable analysis revealed that age (≥65 years), smoking index (≥600), body mass index (≤18.5 kg/m2), interstitial pneumonia, values for percentage of predicted vital capacity (≤9.4%) and lobectomy were risk factors for NLCD. Patients who underwent segmentectomy had significantly better 5-year OS than those who underwent lobectomy, after propensity score matching (94.6% vs 90.4%, P = 0.027). Patients with high comorbidities (patients with ≥2 of the following risks: age ≥65 years, smoking index ≥600, body mass index ≤18.5 kg/m2, Charlson Comorbidity Index ≥1, values for percentage of predicted vital capacity ≤96.4%) who underwent segmentectomy had a better 5-year OS than those who underwent lobectomy (92.8% vs 87.8%, P = 0.016). However, there was no difference in 5-year OS between segmentectomy and lobectomy in patients with low comorbidities (98.5% vs 97.4%, P = 0.867).

Conclusions: The impact of lobectomy and segmentectomy on NLCD depends on the extent of the patients' comorbidities.

Keywords: Comorbidity; Lobectomy; Non-lung cancer death; Risk factor; Segmentectomy.

MeSH terms

  • Aged
  • Carcinoma, Non-Small-Cell Lung*
  • Humans
  • Lung / pathology
  • Lung Neoplasms*
  • Neoplasm Staging
  • Pneumonectomy / adverse effects
  • Retrospective Studies
  • Risk Factors